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Abstract In gastric cancer, hemostatic system components
contribute to cancer progression, as activation of factor X
(FX) was observed. The protein Z (PZ)/protein Z-dependent
protease inhibitor (ZPI) complex inhibits factor Xa proteolytic
activity. The purpose of this study was to determine the
distribution of ZPI and PZ in relation to FX, and prothrombin
fragment (F1+2), a standard marker for blood coagulation
activation, in human gastric cancer tissue. ABC procedures
and a double staining method employed polyclonal antibodies
against PZ, FX, and F1+2 and a monoclonal antibody against
ZPI. In situ hybridization (ISH) methods employed biotin-
labeled 25-nucleotide single-stranded DNA probes directed to
either PZ or ZPI mRNAs. FX and components of PZ/ZPI
coagulation inhibitory system were observed in cancer cells.
F1+2 was observed in gastric cancer cells as well. Double
staining studies revealed FX/PZ, FX/ZPI, and PZ/ZPI co-
localization on gastric cancer cells. ISH studies demonstrated
the presence of PZ mRNA and ZPI mRNA in gastric cancer
cells indicating induced synthesis of these proteins. The co-
localization of PZ/ZPI and FX in gastric cancer cells indicates
in loco that these proteins may play a role in anticoagulant
events at the tumor tissue.
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Introduction
Gastric cancer is one of the leading causes of cancer-related
death in Europe [1]. Thromboembolism complicates the
course of gastric cancer in approximately 15 % of these cases
[2]. These include, inter alia, deep vein thrombosis, portal vein
thrombosis, Budd–Chiari syndrome, nonbacterial thrombotic
endocarditis, pulmonary thromboembolism, as well as
disseminated intravascular coagulation [2]. Thromboembolic
complications may be the first manifestation of gastric cancer
or occur during the treatment (e.g., surgery) or disease
progression [2]. Evidence indicates that blood coagulation
activation proceeds not exclusively in blood vessels but also
in gastric cancer tissue [2]. Tumor-specific activation of factor
X (FX) in cancer patients has been reported, which suggests
an important role for this stage of coagulation activation in
hemostatic system alterations during malignant tumor
progression [3, 4].
That hemostatic system components contribute to cancer
growth and dissemination has been well-documented [4–7].
Factor Xa activity, and consequently the rate of thrombin
generation, is precisely controlled by several inhibitory
mechanisms such as tissue factor pathway inhibitor (TFPI),
antithrombin, and the protein C (PC) system [8]. A previous
study revealed that while FX was present in association with
gastric cancer cells, TFPI was not observed in this localization
[2]. Furthermore, PC was detected in association with gastric
cancer cells and endothelial cells (ECs), but the study failed to
demonstrate the presence of protein S on these cells [2]. The
abovementioned mechanisms suggest inadequate blood
coagulation regulation at the tumor tissue. However, another
mechanism of direct FXa inhibition, derived from the
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concerted activity of protein Z (PZ) and the protein Z-
dependent protease inhibitor (ZPI), has been reported
[9–12]. In this process, PZ, lacking any enzymatic function,
serves as a co-factor in the reaction of FXa inhibition via ZPI
[10, 11, 13, 14]. The reaction rate is increased by PZmore than
1,000-fold, which efficiently facilitates reduced thrombin
generation [10]. The PZ/ZPI complex limits the coagulation
response prior to the formation of the prothrombinase
complex. Protein Z and ZPI circulate in plasma forming a
complex. PZ interacts with FXa in the presence of membrane
phospholipids, which kinetically optimizes the inhibition of
membrane-associated FXa by ZPI [15–17]. ZPI can be also
activated by glycosaminoglycans on the ECs surface and
inhibits FXa that escapes from procoagulant phospholipids
[18]. Appropriate inhibition of FXa via the PZ/ZPI system
requires the presence of the inhibitory proteins and their precise
co-localization at the tumor site. In this regard, there is scant
data concerning PZ/ZPI inhibition of FX in gastric cancer
tissue.
The aim of this study was to analyze the solid-phase
interaction between expression of FX and PZ/ZPI in relation
to blood coagulation activation, indicated by the potential
presence of prothrombin fragment F1+2 in human gastric
cancer. Furthermore, in order to determine the potential origin
of PZ and ZPI, we also examined the expression of mRNAs
encoding PZ and ZPI in these tumor sections.
Materials and methods
Studies were performed on gastric cancer sections obtained
during surgery of previously untreated gastric cancer patients.
Normal gastric tissues, derived from neoplasm-free resection
margins, were also obtained during surgery for comparison.
The study protocol was approved by the local ethics
committee of the Medical University in Bialystok, Poland.
Informed consent was obtained from 15 patients.
Histopathologic examination of tissue fragments revealed
adenocarcinomas G2 in 11 cases and G3 in 4 cases. Clinical
stage of the disease was assessed as T2-3N0M0. The tissues
were fixed in buffered 4 % formalin. Immunohistochemical
(IHC) procedures were performed according to the avidin–
biotin complex technique (ABC) using reagents (Vectastain
Kits, Vector Laboratories, Burlingame, CA, USA) described
in detail elsewhere [19]. A semiquantitative analysis of protein
expression, based on the percentage of positive staining
cancer cells and the intensity of the staining, was performed
exclusively for cancer cells as well [20, 21]. Immunoreactive
score values ranging between 1 and 4 were interpreted as
weak, 5 and 8medium, and 9 and12 strong protein expression,
respectively [20, 21]. A monospecific polyclonal antibody
against homogeneous plasma-derived human PZ was
prepared in rabbits, and then purified from immune sera by
protein A-Sepharose chromatography [22]. Specific mouse
monoclonal anti-human ZPI IgM (4249.2) was a generous
gift from Dr. George J. Broze Jr (Division of Hematology,
Barnes-Jewish Hospital, St. Louis, MO, USA) [23].
Polyclonal antibodies directed to coagulation FX and F1+2
were generously provided by Dr. David Stump (Genentech,
South San Francisco, California) [24]. In the control
specimens, primary antibody was omitted from the procedure.
In the ABC IHC procedure, antigen staining was detected by
the dark brown reaction product.
The Dako EnVisionTM (Dako, Carpinteria CA, USA)
protocol, provided by the manufacturer utilizing the
commercially available Dako EnVisionTM kit (Dako,
Carpinteria CA, USA), was introduced in IHC double staining
studies. Antibodies against FX, PZ, and ZPI, which were
applied in the double staining procedure, were the same as
those used in the ABC IHC study.
The IHC double staining study was aimed to directly
compare the precise localization of the following:
& FX and PZ (FX was visualized as dark brown staining,
whereas PZ as red reaction product)
& FX and ZPI (factor X was visualized as red staining,
whereas ZPI as dark brown reaction product)
& PZ and ZPI (PZ was visualized as red reaction product,
while ZPI as dark brown staining)
The in situ hybridization (ISH) protocol employed biotin-
labeled 25-nucleotide single-stranded DNA probes: (probe
sequence: 5′ biotin-CGTCATACCGCATGTGCACATGGAC-
biotin 3′) specific for PZ mRNA [22], (probe sequence: 5′
biotin-GCCATCGTGCCTCATGGAGATCTTT -biotin 3′)
specific for ZPI mRNA [23]. The probes were synthesized by
Sigma-Aldrich, Poznan, Poland, and the ISH protocol of R&D
Systems (R&DSystems,Minneapolis,MN,USA)was followed.
Hybrids were detected using rabbit anti-biotin monoclonal
antibodies according to the IHC ABC technique associated with
ImmunoMax amplification procedure, which was described in
detail elsewhere [25, 26]. Negative controls were based on
hybridization without addition of the molecular probe and
incubation of slides in RNase A solution (R&D Systems,
Minneapolis, MN, USA) before hybridization. Reaction
products appeared as dark brown staining.
Two independent observers provided visual assessment of the
protein and mRNA expressions in ten consecutive high-power
fields. The results of IHC and ISH studies of gastric cancer
tissues were compared with the results obtained in respective
normal gastric tissues, which were processed simultaneously.
Results
In gastric cancer, FX and components of the PZ/ZPI
coagulation inhibitory system were observed in association
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with cancer cell bodies (Fig. 1a, b, c; Table 1). Furthermore,
F1+2, indirectly indicating extravascular activation of blood
coagulation at the tumor site [24], was also detected in
association with cancer cells (Fig. 1d; Table 1).
Additionally, both PZ and ZPI were observed in
association with ECs of small blood vessels supplying the
gastric tumor, and in tumor-associated macrophages (TAMs)
(Fig. 1b, c).
The IHC double staining studies documented strong co-
localization of PZ and FX as well ZPI and FX in association
with cancer cells (Fig. 1e, f). Additionally, co-localization of
ZPI and PZ was observed in gastric cancer cells (Fig. 1g).
The presence of ZPI and PZ mRNA were observed in
neoplastic cells of gastric cancer (Fig. 2a, b). Neither PZ nor
ZPI mRNA expressions were observed in normal gastric
tissue (Fig. 2c, d).
Discussion
Activation of FX is thought to be an important step in blood
coagulation activation in malignancy [3–5]. A plethora of
coagulation inhibitory mechanisms (among them PZ/ZPI
system) are recognized to counterbalance the activated
coagulation cascade [8, 9, 11, 14, 15]. The present study
revealed the presence of PZ and ZPI in association with ECs
lining vessels that supply nutrients to the gastric cancer,
suggesting that the PZ-ZPI complex may contribute to
limiting the rate of intravascular thrombin generation.
Similarly, in non-small-cell lung cancer (NSCLC) tissue, both
ZP and ZPI in association with ECs were demonstrated,
whereas the presence of FX and PZ but not ZPI was revealed
in colon cancer tissue [27, 28]. Contrary to previously
published reports that human ECs are capable of synthesizing
Fig. 1 Specific staining (brown




coagulation factor X-FX (a),
against protein Z-PZ (b) and
against prothrombin fragment
F1+2 (d), as well as a
monoclonal antibody against
protein Z-dependent protease
inhibitor (ZPI) (c). Solid arrows
indicate staining of tumor cell
bodies in gastric cells, dotted
arrows of endothelial cells,




Specific double staining Dako
EnVisionTM technique (e , f , g)
using polyclonal antibodies
against FX and PZ as well as the
monoclonal antibody directed to
ZPI. e FX and ZPI (FX was
visualized as dark brown reaction
product, whereas PZ as red
staining), f FX and PZ (factor X
was visualized as red reaction
product, whereas ZPI as dark
brown staining), g PZ and ZPI
(PZ was visualized as red
staining, while ZPI as dark brown
reaction product). The two colors
are overlapping indicating co-
expression of both proteins in
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PZ [29, 30] and the presence of mRNAs encoding ZP or ZPI
was demonstrated in colon cancer tissue [27], neither PZ nor
ZPI mRNAs were observed in association with ECs in the
present study. This suggests a blood-borne origin of both
proteins in this localization.
To date, the evidence on the impact of ZPI/PZ on blood
coagulation in cancer is vague. Of particular interest, the
intron F G79A polymorphism of the PZ gene in cancer
patients did not result in any coagulation abnormalities [31].
Furthermore, lower PZ plasma levels in cancer patients in
comparison to a control group were reported, and decreasing
PZ concentrations coincident with cancer progression were
observed [32]. Interestingly, methylome analysis and
integrative profiling of human hepatocellular carcinoma
identified PZ as a tumor-suppressor gene [33]. Of note,
decreased blood levels of PZ in acute leukemia and acute
lymphoblastic leukemia patients were demonstrated, which
correlated with increased episodes of bleeding in the latter
subgroup of the patients [34].
It is a well-known notion that blood coagulation activation
also proceeds extravascularly in tumor tissue [5]. Interestingly,
tissue factor-dependent coagulation in human gastric cancer
tissue was reported [2]. The authors documented the presence
of cross-linked fibrin, the final product of blood coagulation,
at gastric cancer sites [2]. Furthermore, they observed the
expression of F1+2, which is a by-product formed during
thrombin generation from the parent molecule, prothrombin
[8, 24]. This indicator of extravascular blood coagulation in
cancer tissue was found in association with gastric cancer
cells. This was of special interest because our ABC IHC
studies revealed the presence of both proteins (PZ and ZPI)
and FX in gastric cancer cells. Furthermore, the double
staining procedures revealed strict co-localization of PZ/ZPI
system components, along with the expression of FX in
gastric cancer cells in loco. Similar results were observed in
colon cancer and NSCLC [27, 28]. Recently, Vasse [17]
proposed the hypothesis that the major role of the PZ/ZPI
system is to avoid the local tissue deposition of fibrin.
However, this seems not to be the case in gastric cancer tissue.
The presence of F1+2 at the tumor site suggests that the PZ/
ZPI regulatory mechanism is insufficient at fully inhibiting
blood activation in the strict vicinity of cancer cells. However,
it should be recognized that the complex formed between ZPI
and FXa is less stable than other serpin-protease complexes,
and that the PZ/ZPI complex is unable to completely
neutralize FXa catalytic activity under normal conditions
[17]. Thus, our findings raise questions on the potential role
of the PZ/ZPI system in this localization. Various non-
hemostatic processes contributing to cancer progression were
recognized to be triggered by blood coagulation inhibitors
(reviewed in details elsewhere) [7]. Of note, our study
demonstrated mRNAs encoding PZ and ZPI synthesis (apart
from respective proteins expression) in gastric cancer cells,
pointing to the constitutive expression of PZ and ZPI in gastric
cancer cells. Similar findings were observed in human breast
and colon cancer tissues [22, 23, 27]. Pancreatic endocrine
cancers as well as enterochromaffin and neuroendocrine
carcinoma cells were characterized by overexpression of ZPI
mRNA in both primary and metastatic tumors [35, 36].
Table 1 Median immunoreactive score (IRS) values of cancer cell
expression of coagulation factor X (FX), protein Z (PZ), protein Z-
dependent protease inhibitor (ZPI) and prothrombin fragment F1+2
(F1+2) in gastric cancer. ABC immunohistochemical staining
Factor X ZP ZPI F1+2
Median IRS 9.0 8.0 8.0 6.5
Fig. 2 The in situ hybridization
technique employed specific
molecular probes directed to
protein Z mRNA (a) and protein
Z-dependent protease inhibitor
mRNA (b). Dark brown staining
(solid arrows) for the proteins in
tumor cells of gastric cancer
indicating constitutive synthesis
of the proteins in these cells. No
staining for PZ mRNA (c) or ZPI




(a , c , d) and x400 (b)
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However, in lymphoblasts obtained from children suffering
from acute lymphoblastic leukemia, no staining of PZ mRNA
was observed, although some levels of ZPI mRNA were
detected [17]. Noteworthy information was reported
concerning the role of PZ and ZPI in obstetrics and
inflammation, which suggests the potential function of the
above inhibitors not only in the regulation of blood
coagulation but also in local biological processes [17, 22,
23, 37]. Of interest is also the presence of the examined
inhibitors in TAMs, which is in accordance with our previous
findings in breast and colon cancer as well as in NSCLC
tissues [22, 23, 27, 28].
Since the study does not provide insight into the
pathophysiological mechanisms, further investigation is
required.
Conclusions
The co-localization of PZ/ZPI and FX in association with
cancer cells in gastric cancer tissue indicates that the proteins
may play a role in the anticoagulant events at the tumor tissue.
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